Equity · Healthcare
PTGX
NASDAQProtagonist Therapeutics (PTGX)
The line runs 151 USD on 25 August through 141 USD on 29 September, on a scale from 135 to 155. Days the market did not trade hold the previous close, flat.
- Market cap
- 9.2B USD
- P/E (TTM)
- 29.9
- Revenue, year to Dec 2025
- 46.0M USD
- EPS, diluted, year to Dec 2025
- −2.05 USD
- 52-week range
- 64 USD – 151 USD
- Avg volume
- 52.1K
as of Sep 29, 2026
Have Protagonist Therapeutics (PTGX) insiders bought or sold shares recently?
In the 90 days to 8 Nov 2026, Protagonist Therapeutics insiders reported 6 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 10 Oct 2025, show no open-market purchase.
Form 4, 90 days to 8 Nov 2026, newest reported trade 30 Sep 2026
Buys 0Sells 6Net sold $41.44MOther filings 7
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 30 Sep 2026 | Ali AsifChief Financial Officer | Sell | 58,629 | 8.3M USD |
| 10 Sep 2026 | PATEL DINESH V PH DPresident and CEO | Sell | 7,278 | 1.0M USD |
| 09 Sep 2026 | PATEL DINESH V PH DPresident and CEO | Sell | 63,548 | 9.3M USD |
| 08 Sep 2026 | PATEL DINESH V PH DPresident and CEO | Sell | 54,174 | 7.9M USD |
| 11 Aug 2026 | PATEL DINESH V PH DPresident and CEO | Sell | 34,239 | 5.1M USD |
| 10 Aug 2026 | PATEL DINESH V PH DPresident and CEO | Sell | 65,761 | 9.8M USD |
| Sold | 6 open-market sales | 283,629 | $41.44M |
7 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 30 Sep 2026 | Ali AsifChief Financial Officer | Option exercise | 58,629 | 1.4M USD |
| 10 Sep 2026 | PATEL DINESH V PH DPresident and CEO | Option exercise | 7,278 | 157K USD |
| 09 Sep 2026 | PATEL DINESH V PH DPresident and CEO | Option exercise | 63,548 | 1.4M USD |
| 08 Sep 2026 | PATEL DINESH V PH DPresident and CEO | Option exercise | 54,174 | 1.2M USD |
| 03 Sep 2026 | PATEL DINESH V PH DPresident and CEO | Gift | 510 | |
| 11 Aug 2026 | PATEL DINESH V PH DPresident and CEO | Option exercise | 34,239 | 739K USD |
| 10 Aug 2026 | PATEL DINESH V PH DPresident and CEO | Option exercise | 65,761 | 1.4M USD |
Which funds hold Protagonist Therapeutics (PTGX)?
1 of the 45 institutional funds we track reported a Protagonist Therapeutics position for the quarter ended 30 Sep 2026 — a combined 23.7M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 168,373 | 23.7M USD | −1.3% |
What has been filed or recorded for Protagonist Therapeutics (PTGX)?
The filings we hold for Protagonist Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 06 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 06 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,263 shares | 178K USD notional · 0.002% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 53,618 shares | 7.6M USD notional · 0.083% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 3.07 USD | |
| 30 Sep 2026 | Financials | Total assets | 1.1B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 1.1B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 2.29 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.05 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −2.05 USD | |
| 31 Dec 2025 | Financials | Revenue | 46.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −130.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −2.05 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.62 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.55 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.19 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 4.23 USD |
Protagonist Therapeutics (PTGX): frequently asked questions
What did Protagonist Therapeutics shares close at?
Protagonist Therapeutics closed at 141.00 USD on 29 Sep 2026, down 0.70% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Protagonist Therapeutics’ market cap?
Protagonist Therapeutics is worth 9.2B USD by market value as of 29 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Protagonist Therapeutics’ P/E ratio?
Protagonist Therapeutics has a price-to-earnings ratio of 29.9, as of 29 Sep 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Protagonist Therapeutics’ revenue?
Protagonist Therapeutics reported revenue of 46.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Protagonist Therapeutics insiders bought or sold shares recently?
In the 90 days to 8 Nov 2026, Protagonist Therapeutics insiders reported 6 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 10 Oct 2025, show no open-market purchase. A further 7 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Protagonist Therapeutics?
1 of the 45 funds we track reported a Protagonist Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Protagonist Therapeutics last report earnings?
Protagonist Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 3.07 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings